Tefinostat

For research use only. Not for therapeutic Use.

  • CAT Number: I009740
  • CAS Number: 914382-60-8
  • Molecular Formula: C28H37N3O5
  • Molecular Weight: 495.62
  • Purity: ≥95%
Inquiry Now

Tefinostat(Cat No.:I009740)is a selective histone deacetylase (HDAC) inhibitor that primarily targets HDAC1, HDAC3, and HDAC9. It is designed as an anti-cancer agent, particularly for hematological malignancies such as chronic myelomonocytic leukemia (CMML). Tefinostat works by promoting histone acetylation, leading to the reactivation of tumor suppressor genes, inhibition of cell proliferation, and induction of apoptosis in cancer cells. Its selective targeting of HDACs aims to minimize off-target effects and toxicity. Tefinostat is also being explored for its potential in combination therapies for improved cancer treatment outcomes.


Catalog Number I009740
CAS Number 914382-60-8
Synonyms

CHR-2845; CHR 2845; CHR2845; Tefinostat;cyclopentyl (S)-2-((4-(8-(hydroxyamino)-8-oxooctanamido)benzyl)amino)-2-phenylacetate

Molecular Formula C28H37N3O5
Purity ≥95%
Target Epigenetics
Solubility Soluble in DMSO, not in water
Storage 0 - 4 °C for short term, or -20 °C for long term
IUPAC Name cyclopentyl (2S)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate
InChI InChI=1S/C28H37N3O5/c32-25(14-6-1-2-7-15-26(33)31-35)30-23-18-16-21(17-19-23)20-29-27(22-10-4-3-5-11-22)28(34)36-24-12-8-9-13-24/h3-5,10-11,16-19,24,27,29,35H,1-2,6-9,12-15,20H2,(H,30,32)(H,31,33)/t27-/m0/s1
InChIKey GLNWREBYRLDPQP-MHZLTWQESA-N
SMILES C1CCC(C1)OC(=O)C(C2=CC=CC=C2)NCC3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO
Reference

</br>1:The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S.Oncotarget. 2016 Mar 29;7(13):16650-62. doi: 10.18632/oncotarget.7692. PMID: 26934551 Free PMC Article</br>2:A phase I first-in-human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA, Davidson AH, Wells G, Needham L, Bawden L, Toal M, Hooftman L, Debnam PM.Br J Haematol. 2013 Jul;162(2):191-201. doi: 10.1111/bjh.12359. Epub 2013 May 7. PMID: 23647373

Request a Quote